Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ProMetic Life Sciences Inc Develops And Commercializes Alpha1-Antitrypsin As Second Plasma-Derived Orphan Drug Product


Wednesday, 14 Aug 2013 07:00am EDT 

ProMetic Life Sciences Inc announced that the recovery yield for AAT achieved with its PPPS represents a 220% improvement over existing industry average. Combined with a clear regulatory pathway and reimbursement programs in place, the Corporation has selected AAT as its second plasma-derived therapeutic to address a well-defined unmet medical need. There is an estimated 100,000 people affected by AAT deficiency in the USA alone with less than 10% treated. According to the Alpha-1 Foundation, there may be as many as 3% of the 20 million patients suffering from Chronic Obstructive Pulmonary Disease (COPD) that may also have an undetected AAT deficiency. One of the functions of AAT, which is mainly produced in the liver, is to protect the lungs from inflammation caused by infection and inhaled irritants such as tobacco smoke. AAT Deficiency is a genetic condition that leads to a lack of AAT in the blood which can then result in serious lung disease in adults and/or liver disease at any age. 

Company Quote

1.22
0.01 +0.83%
17 Apr 2014